Interleukin-2 Signals During Priming Are Required for Secondary Expansion of CD8+ Memory T Cells
Affiliations
Although interleukin-2 (IL-2) was initially characterized as the primary T-cell growth factor following in vitro activation, less is known about its role in shaping T-cell responses to acute infections in vivo. The use of IL-2- or IL-2-receptor-deficient mice is problematic owing to their early development of autoimmunity, attributable to the central role of IL-2 in the generation, maintenance and function of CD4+CD25+ regulatory T cells. To bypass these inherent difficulties, we have studied the effect of IL-2 on T-cell responses to acute infections by adopting a mixed chimaera strategy in which T cells lacking the high-affinity IL-2 receptor could be studied in an otherwise healthy mouse containing a full complement of regulatory T cells. Here we show that although IL-2 signalling to pathogen-specific CD8+ T cells affects the number of developing effector and memory cells very little, it is required for the generation of robust secondary responses. This is not due to an altered T-cell-receptor repertoire development or selection, and does not reflect an acute requirement for IL-2 during secondary activation and expansion. Rather, we demonstrate a previously unappreciated role for IL-2 during primary infection in programming the development of CD8+ memory T cells capable of full secondary expansion. These results have important implications for the development of vaccination or immunotherapeutic strategies aimed at boosting memory T-cell function.
Sturzbecher L, Bartolomaeus H, Bartolomaeus T, Bolz S, Sekulic A, Ueffing M Front Immunol. 2025; 16:1520188.
PMID: 39975545 PMC: 11835843. DOI: 10.3389/fimmu.2025.1520188.
Yong L, Hutchings C, Barnes E, Klenerman P, Provine N Eur J Immunol. 2024; 55(1):e202451142.
PMID: 39604225 PMC: 11739681. DOI: 10.1002/eji.202451142.
High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity.
Wang Z, Wang M, Li Q, Wu Y, Ying T Biomolecules. 2024; 14(11).
PMID: 39595576 PMC: 11591715. DOI: 10.3390/biom14111399.
Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.
Liu H, Lu Y, Zong J, Zhang B, Li X, Qi H J Nanobiotechnology. 2024; 22(1):663.
PMID: 39465376 PMC: 11520105. DOI: 10.1186/s12951-024-02913-7.
Maurice D, Costello P, Diring J, Gualdrini F, Frederico B, Treisman R Nat Commun. 2024; 15(1):7956.
PMID: 39261466 PMC: 11391060. DOI: 10.1038/s41467-024-52230-8.